This is a preview of subscription content, log in via an institution to check access.
Reference
Goldstein DA, et al. First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis. Journal of Clinical Oncology : 17 Feb 2015. Available from: URL: http://doi.org/10.1200/JCO.2014.58.4904
Rights and permissions
About this article
Cite this article
Bevacizumab not an efficient use of resources in mCRC in the USA. PharmacoEcon Outcomes News 722, 6 (2015). https://doi.org/10.1007/s40274-015-1912-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-1912-5